Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | PAM | P19021 | 1/20 | 0.40 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140974 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL25329304 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL308082 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL24067699 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL25340359 | 0.98 | MAPT (0.57) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL31253447 | 0.98 | MAPT (0.57) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Water SCHEMBL8124987 | 0.98 | MAPT (0.57) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL24378412 | 0.94 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL26864072 | 0.94 | MAPT (0.53) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL12442995 | 0.91 | MAPT (0.55) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | claimed |
| US-11859203-B2 | Cell culture methods | UCB Biopharma SRL (BE) | 2024-01-02 | — | — | US | claimed |
| US-20230372272-A1 | USE OF CYSTINE AND DERIVATIVES THEREOF AS ANTI-THROMBOTIC AND THROMBOLYTIC AGENTS | GEORGIA TECH RESEARCH CORPORATION | 2023-11-23 | — | — | US | claimed |
| EP-4143161-B1 | PROCESS OF MAKING N,N-DIACETYL-L-CYSTINE DISODIUM SALT FROM CYSTINE AND ACETYL CHLORIDE IN METHANOL IN THE PRESENCE OF SODIUM HYDROXIDE | UNILEVER IP HOLDINGS B V (NL) | 2023-11-01 | — | — | EP | claimed |
| EP-4143160-B1 | PROCESS OF MAKING N,N'-DIACETYL-L-CYSTINE | UNILEVER IP HOLDINGS B V (NL) | 2023-11-01 | — | — | EP | claimed |
| EP-4142680-B1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | UNILEVER IP HOLDINGS B V (NL) | 2023-10-18 | — | — | EP | claimed |
| EP-3717631-B1 | CELL CULTURE METHODS | UCB Biopharma SRL (BE) | 2023-08-30 | — | — | EP | claimed |
| EP-4216939-A1 | USE OF CYSTINE AND DERIVATIVES THEREOF AS ANTI-THROMBOTIC AND THROMBOLYTIC AGENTS | Georgia Tech Research Corporation (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230183176-A1 | PROCESS OF MAKING N,N'-DIACETYL-L-CYSTINE | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-06-15 | — | — | US | claimed |
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-05-25 | — | — | US | claimed |
| EP-0727207-A1 | The pharmacological use of certain cystine derivatives | Astra Aktiebolag (SE) | 1996-08-21 | — | — | EP | claimed |
| US-5441976-A | Immunostimulants | AKTIEBOLAGET ASTRA (SE) | 1995-08-15 | — | — | US | claimed |
| US-5385904-A | Organic salts of N,N'-diacetyl cystine | AKTIEBOLAGET ASTRA (SE) | 1995-01-31 | — | — | US | claimed |
| EP-0621862-A1 | ORGANIC SALTS OF N, N'-DIACETYL CYSTINE. | ASTRA AB (SE) | 1994-11-02 | — | — | EP | claimed |
| WO-1993011104-A1 | ORGANIC SALTS OF N, N'-DIACETYL CYSTINE | AB ASTRA (SE) | 1993-06-10 | — | — | WO | claimed |
| EP-0532595-A1 | THE PHARMACOLOGICAL USE OF CERTAIN CYSTINE DERIVATIVES. | ASTRA AB (SE) | 1993-03-24 | — | — | EP | claimed |
| WO-1991018594-A1 | THE PHARMACOLOGICAL USE OF CERTAIN CYSTINE DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1991-12-12 | — | — | WO | claimed |
| US-4724239-A | Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine | MORGAN LEE R (US) | 1988-02-09 | — | — | US | claimed |
| US-4708965-A | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives | MORGAN LEE R (US) | 1987-11-24 | — | — | US | claimed |
| US-4379177-A | Stable dehydrated cocrystalline amino acid food additives | THE PROCTER & GAMBLE COMPANY (US) | 1983-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183176-A1 | PROCESS OF MAKING N,N'-DIACETYL-L-CYSTINE | NAA15, DDC, NMT2 | MAPT 1720/4885KDM4E 4395/4885THRB 3168/4885 |
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CUTA, CBS, SLC7A11 | MAPT 609/4885KDM4E 2928/4885THRB 4847/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | MAPT 1593/4885KDM4E 4306/4885THRB 3865/4885 |
| US-20230372272-A1 | USE OF CYSTINE AND DERIVATIVES THEREOF AS ANTI-THROMBOTIC AND THROMBOLYTIC AGENTS | SERPINC1, SERPINE1, CTH | MAPT 3961/4885KDM4E 4589/4885THRB 2120/4885 |
| US-11859203-B2 | Cell culture methods | CBS, CTH, SLC7A11 | MAPT 3657/4885KDM4E 3920/4885THRB 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.